title: Counselling patients on psychotropic medication: physicians' opinions on the role of community pharmacists.
abstract: OBJECTIVE
  To study physicians' opinions on community pharmacists' involvement in counselling patients on use of psychotropic medication.
  
  
  METHODS
  A postal questionnaire with open-ended questions completed by physicians.
  
  
  METHODS
  A six per cent random sample (n = 759) of the members of the Finnish Medical Association representing physicians working in hospitals, community health centres, private practices and occupational health services (response rate 64%, n = 487).
  
  
  METHODS
  Physicians' opinions concerning community pharmacists' involvement in counselling patients about purpose of the medication and adverse effects of benzodiazepines and neuroleptics.
  
  
  RESULTS
  When classifying opinions into five categories, majority (72%) of the physicians regarded community pharmacists as a provider of comprehensive or at least general information about adverse effects of benzodiazepines, but only 43% about the purpose of the medication. Correspondingly, 60% of the physicians regarded community pharmacists as a provider of comprehensive or general information about adverse effects of neuroleptics, but only 35% about the purpose of the medication. There was a strong correlation between physicians' opinions concerning pharmacists' involvement in counselling patients about the purpose of the medication of benzodiazepines and neuroleptics (Spearman's coefficient 0.667), and about adverse effects of both type of medication (0.668). Male physicians had more fixed opinions, both positive and negative, than female physicians.
  
  
  CONCLUSIONS
  Finnish physicians are still quite critical about community pharmacists involvement in counselling patients on psychotropic medication. Especially with neuroleptics, physicians feel that pharmacists should be cautious when discussing the purpose of the medication if it is excluded from the prescription.
authors.affiliation: Oy Galena Ltd, Kuopio, Finland. tanskanen@galena.fi
authors.forename: P
authors.initials: P
authors.lastname: Tanskanen
authors.forename: M
authors.initials: M
authors.lastname: Airaksinen
authors.forename: A
authors.initials: A
authors.lastname: Tanskanen
authors.forename: H
authors.initials: H
authors.lastname: Enlund
mesh_terms: D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D001569:Benzodiazepines; D003625:Data Collection; D005260:Female; D005387:Finland; D006801:Humans; D008297:Male; D010353:Patient Education as Topic; D010594:Pharmacies; D010595:Pharmacists; D010820:Physicians; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D012737:Sex Factors
chemical_list: D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D001569:Benzodiazepines